Clinical Trial Update: Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating vorinostat with or without bortezomib for refractory or recurrent cutaneous T-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Velcade (bortezomib)
• Zolinza (vorinostat)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Lymphoma | Phase 3 | Status: WITHDRAWN